Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02435940
Other study ID # FFB-Registry-01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 2014
Est. completion date June 2037

Study information

Verified date February 2023
Source Foundation Fighting Blindness
Contact Registry Coordinator
Phone 800-683-5555
Email Coordinator@MyRetinaTracker.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.


Description:

My Retina Tracker Registry provides two portals for data entry and review. Initial registration in the My Retina Tracker Registry is initiated by a participant, not a clinician. Using the participant portal, the participant establishes a username and password, is guided through on-line informed consent, and can then use an interactive guide to record their ophthalmic and family history, genotype and other subjective diagnosis-related and general health information. Drop-down menus and standardized vocabulary are used for database consistency. They may also attach documents, such as medical records, to maintain their personal medical files on their disease. Participants are encouraged to update their profiles regularly to create a longitudinal history of their disease. Participants can see aggregated data for all other participants in the registry and compare their own disease and status to others. After a profile has been established, Registry members may ask their clinician or genetic counselor to add specific ophthalmic exam and measurement results to the profile. This is done through the clinical portal which also uses a series of drop-down menus to expedite entry and standardize data. Clinicians cannot see the participant data when adding the clinical exam data. Participants are encouraged to collect this data at each medical exam, to create a longitudinal clinical data set. Access to de-identified data or study recruitment assistance is available to qualified investigators who may inquire by contacting Coordinator@MyRetinaTracker.org. A process that maintains patient anonymity and privacy protection, exists for researchers with Institutional Review Board-approved projects who wish to contact registry participants of interest.


Recruitment information / eligibility

Status Recruiting
Enrollment 20000
Est. completion date June 2037
Est. primary completion date June 2037
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Diagnosed with an inherited retinal degenerative disease OR Exclusion Criteria: - Glaucoma only - Diabetic retinopathy only - Non-retinal disease - Not heritable retinal disease

Study Design


Related Conditions & MeSH terms

  • Abetalipoproteinemia
  • Achromatopsia
  • Bardet-Biedl Syndrome
  • Bassen-Kornzweig Syndrome
  • Batten Disease
  • Best Disease
  • Blindness
  • Choroidal Dystrophy
  • Choroideremia
  • Color Vision Defects
  • Cone Dystrophy
  • Cone-Rod Dystrophy
  • Congenital Stationary Night Blindness
  • Enhanced S-Cone Syndrome
  • Eye Diseases
  • Eye Diseases Hereditary
  • Eye Diseases, Hereditary
  • Fundus Albipunctatus
  • Goldmann-Favre Syndrome
  • Gyrate Atrophy
  • Juvenile Macular Degeneration
  • Kearns-Sayre Syndrome
  • Leber Congenital Amaurosis
  • Macular Degeneration
  • Neuronal Ceroid-Lipofuscinoses
  • Night Blindness
  • Refsum Disease
  • Refsum Syndrome
  • Retinal Disease
  • Retinal Diseases
  • Retinitis
  • Retinitis Pigmentosa
  • Retinitis Punctata Albescens
  • Retinoschisis
  • Rod Dystrophy
  • Rod Monochromacy
  • Rod-Cone Dystrophy
  • Stargardt Disease
  • Syndrome
  • Usher Syndrome
  • Usher Syndromes
  • Vitamin A Deficiency

Locations

Country Name City State
United States Foundation Fighting Blindness Columbia Maryland

Sponsors (1)

Lead Sponsor Collaborator
Foundation Fighting Blindness

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Rare Diagnoses Within the Inherited Retinal Degenerative Disease Category as Defined by Clinical Evaluation Participant profiles broken out be disease category and genetic diagnosis Data collection is ongoing, up to 20 years.
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2